Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Kymera Therapeutics Inc (NQ: KYMR )

31.45 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 31.45
Bid (Size) 12.65 (1)
Ask (Size) 35.72 (1)
Prev. Close 31.45
Today's Range 31.45 - 31.45
52wk Range 9.600 - 45.31
Shares Outstanding 55,307,775
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Biotechs Race to Develop New Treatments as Global Pancreatic Cancer Market Size Expected to Reach $7.5 Billion by 2033
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:KYMR),(NASDAQ:GILD),(OTCQX:RHHBY),(NASDAQ:AMGN) EQNX::TICKER_END 
Via FinancialNewsMedia
Cracking The Code: Understanding Analyst Reviews For Kymera Therapeutics
Via Benzinga

Performance

YTD
+24.06%
+24.06%
1 Month
-6.20%
-6.20%
3 Month
-20.38%
-20.38%
6 Month
+17.18%
+17.18%
1 Year
+39.22%
+39.22%

More News

Read More
Kymera Therapeutics Presents New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Demystifying Kymera Therapeutics: Insights From 5 Analyst Reviews
Via Benzinga
Kymera Therapeutics Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)
Via Benzinga
Breaking Down Kymera Therapeutics: 4 Analysts Share Their Views
Via Benzinga
Biotechs Race to Develop New Treatments as Global Pancreatic Cancer Market Size Expected to Reach $7.5 Billion by 2033
From FN Media Group LLC
Via GlobeNewswire
Kymera Therapeutics Presents New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Kymera Therapeutics to Participate in Upcoming June Investor Conferences
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Kymera Therapeutics to Present New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Kymera Therapeutics Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the ATS Annual Meeting
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Kymera Therapeutics to Present New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Kymera Therapeutics to Participate in Upcoming May Investor Conferences
From Kymera Therapeutics, Inc.
Via GlobeNewswire
KYMR Stock Earnings: Kymera Therapeutics Beats EPS, Misses Revenue for Q1 2024
Via InvestorPlace
Kymera Therapeutics Announces First Quarter 2024 Financial Results and Provides a Business Update
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Kymera Therapeutics to Report First Quarter 2024 Financial Results on May 2
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Kymera Therapeutics Announces Scientific Presentations at the American Association for Cancer Research 2024 Annual Meeting
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Kymera Therapeutics Presents Preclinical Data for STAT6 and TYK2 First-In-Class, Oral Degrader Immunology Programs at the American Academy of Dermatology Annual Meeting
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Kymera Therapeutics to Participate in Upcoming March Investor Conferences
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Piper Sandler Maintains Overweight Rating for Kymera Therapeutics: Here's What You Need To Know
Via Benzinga
Kymera Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Kymera Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on February 22
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Earnings Scheduled For February 22, 2024
Via Benzinga
Kymera Therapeutics to Present in Fireside Chat at the Guggenheim Healthcare Conference
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Kymera Therapeutics Outlines Key 2024 Objectives and Strategy to Progress Leading Portfolio of Immunology and Oncology Programs
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.